前加巴林在埃及被重新归类为受控物质对 gabapentinoid 和阿片类药物利用的影响:一项重复的横截面研究
Araniy Santhireswaran1, Simon LaRue2, Shanzeh Chaudhry1
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
PloS one
|December 5, 2025
概括
2019年埃及的普雷加巴林重新分类显著减少了其使用,但增加了 gabapentin 的销售. 这一政策转变凸显了持续监测的必要性,以管理疼痛治疗中的意外后果.
科学领域:
- 药物经济学和药物政策
- 公共卫生和流行病学
- 疼痛管理治疗方法 治疗方法
背景情况:
- 作为止痛药的普雷加巴林具有显著的滥用潜力.
- 埃及当局于2019年8月将普雷加巴林归类为一种受控物质,以打击越来越多的滥用行为.
- 这一政策旨在规范普雷加巴林的分销,并制其滥用.
研究的目的:
- 评估埃及2019年普雷加巴林重新分类政策的影响.
- 评估 gabapentinoid (pregabalin 和 gabapentin) 和阿片类药物销售后政策的变化.
- 了解替代效应和对疼痛管理的更广泛影响.
主要方法:
- 使用自回归集成移动平均线 (ARIMA) 模型进行中断时间序列分析.
- 分析了从2012年至2023年期间的普雷加巴林, gabapentin 和阿片类药物的季度销售量数据.
- 标准化每1000个人销售数据,计算政策后3,6和12个月的百分比变化.
主要成果:
- 在政策实施后, gabapentinoid 的销售额下降了 67%,而 pregabalin 的销售额下降了 99%, gabapentin 的销售额增加了 198%.
- 阿里马模型显示了对 gabapentinoid 销售的显著短期 (脉冲:p < 0.001) 和长期 (坡道:p = 0.008) 影响.
- 阿片类药物的销售显示了显著的短期增长 (步骤:p = 0.010),在一年内上升到49.5%,而长期没有显著的变化 (道:p = 0.256).
结论:
- 这一政策有效地减少了普雷加巴林的使用,但导致了 gabapentin 使用的大幅增加.
- 调查结果强调了毒品政策干预的复杂性和替代效应的潜力.
- 持续监测对于减轻意外后果和优化政策后的疼痛管理策略至关重要.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
611
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
611
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
888
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
888
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
01:25Analgesia and Pain Management
1.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
813
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
813
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
791
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
791